China Resources Double Crane (600062.SH): DC50292A patch obtains clinical trial approval from the US FDA

This is the translation of the text provided: "Zhixun Finance APP News, CR Double-Crane (600062.SH) announced that recently, the company's wholly-owned subsidiary Beijing Shuanghe Runchuang Technology Co., Ltd. received a letter from the US FDA (the US Food and Drug Administration) approving the clinical trial of DC50292A tablets (hereinafter referred to as "the drug") (IND number: 175068). The DC50292A tablet is intended to be used for the treatment of advanced solid tumors."